Previous studies have identified new diagnostic markers for HBV‐associated hepatocellular carcinoma, such as AFP‐L3 and PIVKA‐II, which have been found to have high specificity but are not routinely used as clinical tests [11, 12]. This evidence concerns the gene AFP and hepatocellular carcinoma.